LGND FY 2023 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$131M-33.1% YoY

Gross Profit

$96M73.3% margin

Operating Income

$12M9.1% margin

Net Income

$52M39.7% margin

EPS (Diluted)

$2.94

Cash Flow

Operating Cash Flow

$50M

Free Cash Flow

-$4M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$787M

Total Liabilities

$86M

Stockholders' Equity

$701M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$131M	$196M	-33.1%
Gross Profit	$96M	$143M	-32.9%
Operating Income	$12M	$3M	+293.2%
Net Income	$52M	-$33M	+256.3%